Background {#Sec1}
==========

Castration-resistant prostate cancer (CRPC) is associated with impaired health-related quality of life (HRQoL). This reflects, in part, the disease process itself \[[@CR1]--[@CR3]\], with HRQoL continuing to deteriorate as the disease progresses \[[@CR2], [@CR4]\]. In addition, treatment-related side effects can have a negative impact on HRQoL \[[@CR2], [@CR3]\]. While metastatic CRPC (mCRPC) had previously been associated with rapid disease progression and relatively short median survival (approximately 18 months) \[[@CR2], [@CR4]\], in recent years, several new treatments have shown a survival benefit \[[@CR5]\]. Accordingly, as more patients receive treatment over longer periods, the importance of measuring HRQoL is increasingly recognized. For example, the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) recommends serial assessment of HRQoL in clinical trials of treatments for progressive CRPC \[[@CR6]\]. A number of tools are available to assess HRQoL in CRPC, including disease-specific questionnaires such as Functional Assessment of Cancer Therapy--Prostate (FACT-P) \[[@CR7]\], cancer-specific questionnaires such as the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire \[[@CR8]\], and generic (i.e. non--disease-specific) questionnaires, such as the EQ-5D \[[@CR9], [@CR10]\].

Development of CRPC is due, in part, to sustained androgen receptor (AR) signaling despite castrate levels of testosterone \[[@CR11], [@CR12]\]. Thus, the AR is a key target for developing novel treatments for CRPC. Enzalutamide is a potent AR signaling inhibitor that impairs three stages of the AR signaling pathway: nuclear translocation of the receptor, DNA binding to AR response elements, and recruitment of co-activators \[[@CR11]\]. It has a higher affinity for the AR than the first-generation agent, bicalutamide, and lacks partial agonist effects with higher AR expression \[[@CR11]\]. Enzalutamide has been evaluated in both chemotherapy-treated (AFFIRM) and chemotherapy-naïve (PREVAIL) men with mCRPC. In both settings, it was associated with significant improvements in overall and radiographic progression-free survival compared with placebo \[[@CR13], [@CR14]\].

Patient HRQoL was assessed in the AFFIRM trial using FACT-P and the Brief Pain Inventory Short Form (BPI-SF) and in the PREVAIL trial using FACT-P and EQ-5D \[[@CR13]--[@CR16]\]. In AFFIRM, overall improvement in HRQoL (i.e. FACT-P total score) was reported by a greater proportion of patients receiving enzalutamide than those receiving placebo (42% vs. 15%; *P* \< .0001) \[[@CR16]\]. PREVAIL (NCT01212991) notably recruited patients with a relatively low symptom burden, and in addition to assessing FACT-P, it was the first randomized controlled trial to report EQ-5D responses in an exclusively chemotherapy-naïve mCRPC population \[[@CR15]\].

EQ-5D outcomes from PREVAIL, such as change in EQ-5D index and visual analogue scale (VAS), were summarized by Loriot et al. \[[@CR15]\]; however, only limited data were provided in that earlier paper as it reported on all HRQoL instruments included in PREVAIL (FACT-P, BPI-SF, and EQ-5D). A more in-depth exploration of EQ-5D dimensions can provide greater insight into drivers of change in the instrument's two summary measures, particularly the EQ-5D index, and help reveal any patterns in those changes. Likewise, alternative methods to summarize change in the EQ-5D descriptive system, such as the Paretian Classification of Health Change (PCHC) \[[@CR17]\], can help to identify further differences between treatments not explored in the earlier paper. Additionally, aspects such as the number of patients describing themselves in full health on the EQ-5D system can give a fuller picture of the nature of the study population and the effect of treatment over time. Such information can also be useful for planning future studies using EQ-5D in this population.

This paper, therefore, reports the results of a secondary analysis of data from the PREVAIL trial to provide greater insight into patterns of change on EQ-5D dimensions in PREVAIL and how they relate to changes on the EQ-5D index and VAS. This additional analysis should enhance understanding of the patient experience of treatment and provide useful information for those working with the EQ-5D in this field.

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

Full details on the study design, patient eligibility criteria, and conduct of the study have been reported elsewhere \[[@CR14]\]. Briefly, PREVAIL was a multinational, phase 3, randomized, double-blind, placebo-controlled trial. Patients aged ≥18 years were included if they had confirmed mCRPC, despite androgen-deprivation therapy, and were chemotherapy naïve. Additionally, patients had to be asymptomatic or mildly symptomatic (i.e. score of 0--3 on the Brief Pain Inventory Short Form questionnaire) with a good performance status (i.e. Eastern Cooperative Oncology Group \[ECOG\] Performance Status of 0 or 1). Treatment with oral enzalutamide (160 mg once daily) or placebo continued until the occurrence of unacceptable adverse events, confirmed radiographic progression, or a skeletal-related event warranting initiation of chemotherapy.

EQ-5D questionnaire and outcomes {#Sec4}
--------------------------------

Patient HRQoL was assessed using the 3L version of EQ-5D, an international, standardized questionnaire for evaluating HRQoL \[[@CR9], [@CR10], [@CR18]\]. It consists of five dimensions (Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression), each of which have three levels of problems (1, no problems; 2, some problems; and 3, extreme problems). It also includes the EQ-5D VAS to assess patients' current health status (scale 0--100, where 0 = worse imaginable health state and 100 = best imaginable heath state). Results for the dimensions are combined to give a unique EQ-5D health state (or profile) for each patient, consisting of a five-digit code; for example, state 11111 indicates no problems in any dimension \[[@CR18]\]. By applying weights derived from the general population \[[@CR18], [@CR19]\], health states can then be converted to a preference-weighted summary score, or EQ-5D index on which a score of 1 corresponds to full health, while 0 represents a state so bad it is considered equivalent to death. Thus, for both measures, higher scores indicate better HRQoL.

In the current study, EQ-5D was assessed at baseline and week 13, then every 12 weeks thereafter until drug discontinuation. EQ-5D index scores were derived by applying weights from the UK general population \[[@CR20]\].

Statistical analyses {#Sec5}
--------------------

EQ-5D questionnaire completion rates were calculated at each assessment time point by dividing the number of patients who answered all of the EQ-5D items by the total number of patients available (i.e. those who were still on study drug).

Analyses were performed on the intention-to-treat population, which included all patients who were randomized into the study, using data from all EQ-5D respondents. Results are presented up to week 61 only in view of the reduction in the effective sample size during follow-up (see [Results](#Sec6){ref-type="sec"}).

Least squares mean (LSM) values (with 95% confidence intervals \[CIs\]) and changes from baseline in EQ-5D index and EQ-5D VAS scores (based on data from all time points) were estimated after adjusting by baseline EQ-5D index/EQ-5D VAS, age, fatigue score, pain score, and country in a mixed model for repeated measurements.

Average changes from baseline were estimated by dividing the cumulated change from baseline by the number of weeks of follow-up. For this analysis, LSM (standard error) and 95% CI of the difference between study arms in changes from baseline were estimated after adjusting by baseline EQ-5D index/EQ-5D VAS, age, fatigue score, pain score, and country in an analysis of covariance model.

For each EQ-5D dimension, the proportion of patients reporting no, some, or extreme problems was summarized at each time point. Additionally, the proportion of patients with an EQ-5D index score of 1 (full health) was summarized. EQ-5D data were also evaluated using the PCHC \[[@CR17]\] whereby patients' health was classified as: improved (improvement on at least one EQ-5D dimension and no worsening on any other dimension), worsened (deterioration on at least one EQ-5D dimension and no improvement on any other dimension), mixed (improved on at least one dimension and worsened on at least one other dimension), or no change. Finally, time-to-event analyses were used to estimate the benefit of enzalutamide compared to placebo in delaying or preventing deterioration in patients' health. Inverted hazard ratios (1/HR) and 95% CIs were derived for the following endpoints using a Cox proportional hazards model: divergence from baseline "full health" (EQ-5D health state of 11111; this variable was applicable only to those patients in full health at baseline), first decrease on EQ-5D VAS, first worsening on PCHC, and first deterioration on selected dimensions (with Pain/Discomfort being of particular interest). The model was adjusted for the following baseline factors: age, fatigue score, pain score, geographic region, and baseline EQ-5D index or corresponding dimension value. The results can be interpreted as the reduction in each event rate for patients taking enzalutamide versus those receiving placebo.

An additional analysis explored the possibility of an association between changes on the Pain/Discomfort dimension of EQ-5D and changes on the Anxiety/Depression dimension. Odds ratios and 95% CIs were derived up to week 61. Data from patients in both study arms were aggregated for this analysis. A C statistic was used to summarize the strength of the relationship between Anxiety/Depression and Pain/Discomfort dimensions at each time point. For this statistic, a value close to 1 indicates a perfect association (i.e. in all cases, if Pain/Discomfort improves or worsens then so does Anxiety/Depression).

In all statistical analyses, significance is set at *P* \< .05. No correction was made for multiple testing, since EQ-5D variables were considered as secondary, exploratory endpoints in the PREVAIL trial. This was a post hoc analysis and subsequent conclusions should take this into consideration.

Results {#Sec6}
=======

In total, 1717 patients were randomized to receive enzalutamide (*n* = 872) or placebo (*n* = 845). Baseline demographic and disease characteristics, which have been described previously, were well balanced between treatment arms \[[@CR14]\]. At baseline, mean (standard deviation) EQ-5D index scores (enzalutamide, 0.85 \[0.15\]; placebo, 0.84 \[0.17\]) and EQ-5D VAS scores (enzalutamide, 77.2 \[16.7\]; placebo, 75.9 \[17.5\]) were similar between groups. A similar proportion of patients in each group were in full health (index value = 1) at baseline (enzalutamide, 42.5%; placebo, 42.3%).

EQ-5D questionnaire completion rates exceeded 90.0% in both groups at all time points up to week 61. The number of patients available for EQ-5D assessment declined over time due to attrition of patients on study; study drug discontinuation was primarily due to disease progression. As expected, the attrition rate varied between treatment arms. Thus, by week 37 the number of patients with available EQ-5D dimension data had decreased from 857 at baseline to 671 in the enzalutamide group versus a reduction from 826 to 267 in the placebo group; by week 61 these numbers had decreased to 523 and 117 patients, respectively. Data on HRQoL was not collected after study drug discontinuation.

Analysis of individual EQ-5D dimensions (Table [1](#Tab1){ref-type="table"}) showed that the effect of enzalutamide on HRQoL was primarily in the Pain/Discomfort dimension, with significant between-group differences (*P* \< .05) to week 37. Data from individual EQ-5D dimensions also favored enzalutamide in Anxiety/Depression at week 13 (*P* = .006) and Usual Activities at week 25 (*P* = .03). There were no significant between-group differences in the Mobility and Self-care dimensions.Table 1Outcomes on individual EQ-5D dimensions by treatment groupBaselineWeek 13Week 25Week 37Week 49Week 61EQ-5D dimensionsENZA (*n* = 857), %PBO (*n* = 826), %*P* valueENZA (*n* = 809), %PBO (*n* = 624), %*P* valueENZA (*n* = 746), %PBO (*n* = 367), %*P* valueENZA (*n* = 671), %PBO (*n* = 267), %*P* valueENZA (*n* = 610), %PBO (*n* = 176), %*P* valueENZA (*n* = 523), %PBO (*n* = 117), %*P* valueMobility Level 174.9%74.7%0.594074.7%71.3%0.319773.7%70.8%0.582370.4%70.3%0.818366.7%30.9%0.645468.5%71.8%0.7640 Level 2 or 325.1%25.3%25.4%28.8%26.3%29.1%29.7%29.7%33.3%69.1%31.6%28.3%Self-care Level 194.9%93.8%0.172693.9%92.0%0.225394.0%90.6%0.103492.4%91.7%0.284992.3%92.0%0.91866.9%10.2%0.0619 Level 2 or 35.1%6.2%6.1%8.0%6.0%9.3%7.7%8.3%7.7%8.0%93.1%89.7%Usual Activities Level 180.1%80.5%0.968574.9%69.3%0.067577.9%71.8%0.026276.2%76.7%0.358970.8%71.8%0.926672.7%69.8%0.6346 Level 2 or 320.0%19.5%25.1%30.6%22.1%28.2%23.9%23.4%29.3%28.2%27.31%30.2%Pain/Discomfort Level 155.8%58.5%0.462356.0%47.8%0.005159.8%50.7%0.016356.4%47.6%0.047552.6%52.8%0.628152.4%53.9%0.4483 Level 2 or 344.3%41.5%44.1%52.2%40.3%49.4%43.5%52.5%47.5%47.1%47.6%46.2%Anxiety/Depression Level 175.0%72.9%0.069074.4%67.6%0.006076.3%71.0%0.161075.9%72.9%0.502374.0%68.8%0.176270.8%71.8%0.7396 Level 2 or 325.0%27.2%25.6%32.4%23.8%29.1%24.1%27.0%26.0%31.3%29.2%28.2%*ENZA* enzalutamide, *PBO* placeboDifferences refer to the comparison between groups in the percentage of patients with (2 or 3) or without (1) problems in each dimension. They do not take into account whether patients are in level 2 or 3. There were very few patients at level 3 in any dimension, even at 61 weeks. *P* values refer only to the between-group differences

Figure [1](#Fig1){ref-type="fig"} shows the number and proportion of patients with an EQ-5D index value of 1 (full health) at different time points up to week 61. Although there was a tendency for the enzalutamide group to show a greater proportion of patients in health state 11111 up to week 37, the between-group difference was only statistically significant at week 13 (*P* \< .05).Fig. 1Number and proportion of patients in full health (EQ-5D state 11111) at each study visit, by study arm

The PCHC analysis showed a greater proportion of enzalutamide patients reporting improvement than those receiving placebo (Table [2](#Tab2){ref-type="table"}); between group differences were statistically significant (*P* \< .05) at weeks 13, 25, and 49 and approached significance at week 37. A significantly (*P* \< .05) greater proportion of placebo patients reported worsening up to week 25.Table 2Pareto classification of health change classification of changes from baseline in EQ-5D dimensionsEnzalutamide (*n* = 872), n (%)Placebo (*n* = 845), n (%)*P* valueWeek 13*n* = 783 (89.8%)*n* = 605 (71.6%)Worsening208 (26.6%)230 (38.0%)\<0.0001No change337 (43.0%)242 (40.0%)Improvement190 (24.3%)94 (15.5%)\<0.0001Mixed change48 (6.1%)39 (6.5%)Week 25*n* = 726 (83.3%)*n* = 356 (42.1%)Worsening194 (26.7%)123 (34.6%)0.0078No change288 (39.7%)151 (42.4%)Improvement193 (26.6%)64 (18.0%)0.0018Mixed change51 (7.0%)18 (5.1%)Week 37*n* = 649 (74.4%)*n* = 258 (30.5%)Worsening198 (30.5%)95 (36.8%)0.0666No change252 (38.8%)100 (38.8%)Improvement146 (22.5%)43 (16.7%)0.0512Mixed change53 (8.2%)20 (7.8%)Week 49*n* = 594 (68.1%)*n* = 168 (19.9%)Worsening210 (35.4%)61 (36.3%)0.8192No change214 (36.0%)74 (44.1%)Improvement132 (22.2%)22 (13.1%)0.0093Mixed change38 (6.4%)11 (6.6%)Week 61*n* = 507 (58.1%)*n* = 113 (13.4%)Worsening193 (38.1%)51 (45.1%)0.1644No change180 (35.5%)41 (36.3%)Improvement101 (19.9%)18 (15.9%)0.3299Mixed change33 (6.5%)3 (2.7%)

Enzalutamide was statistically superior to placebo in the majority of the time-to-event analyses performed, including time to diverge from full health (*P* \< .0001), time to first decrease in the EQ-5D Index or EQ-5D VAS (both *P* \< .0001), time to first worsening on PCHC (*P* = .0003), and time to first deterioration on the Self-care (*P* = .0019), Pain/Discomfort (*P* \< .0001), and Anxiety/Depression (*P* = .0003) dimensions (Table [3](#Tab3){ref-type="table"}). Adjusted HRs for the analyses with statistically significant results ranged from 0.52 for any worsening from full health at baseline to 0.76 for worsening on the PCHC.Table 3Adjusted estimates of risk reduction of the onset of each deterioration assessment for patients taking enzalutamide vs. placebo (inverted hazard ratios \[HR\] and 95% confidence intervals \[CI\])Deterioration eventsAdjusted 1/HR95% CI*P* valueAny worsening from baseline full health (EQ index = 1)0.520.42--0.65\<0.0001Any decrease in EQ-5D index0.530.48--0.61\<0.0001Any decrease in EQ-5D VAS0.620.55--0.70\<0.0001"Worsening" on PCHC0.760.65--0.880.0003Worsening in EQ-5D dimensions Mobility0.870.68--1.100.2357 Self-care0.600.43--0.830.0019 Usual Activities0.850.70--1.030.1066 Pain/Discomfort0.570.47--0.68\<0.0001 Anxiety/Depression0.660.53--0.830.0003*PCHC* Paretian Classification of Health Change, *VAS* visual analogue scaleRelative risk reduction and 95% CIs from Cox proportional hazards models adjusted by the following baseline factors: age, fatigue score, pain score, geographic region, and baseline EQ-5D index or corresponding dimension value

Finally, results suggest that the risk of worsening in the Anxiety/Depression dimension increased substantially if there was worsening in the Pain/Discomfort dimension (Table [4](#Tab4){ref-type="table"}). Conversely, the chance of improvement in the Anxiety/Depression dimension increased significantly if there was improvement in the Pain/Discomfort dimension. A C statistic analysis indicated a moderate association between improvement (C = 0.54--0.58) or worsening (C = 0.53--0.62) in Pain/Discomfort and improvement or worsening in Anxiety/Depression, respectively, during the study.Table 4Odds ratios for risk of worsening or improvement in EQ-5D anxiety/depression dimension when pain/discomfort dimension worsens or improves, respectively (not by treatment)Odds ratio (95% CI)Week 13 (*n* = 1403)Week 25 (*n* = 1087)Week 37 (*n* = 914)Week 49 (*n* = 770)Week 61 (*n* = 625)Worsening of Anxiety/Depression with worsening Pain/Discomfort2.495 (1.749--3.559)3.623 (2.426--5.410)2.259 (1.431--3.564)2.696 (1.690--4.303)1.457 (0.832--2.554)Improvement in Anxiety/Depression with improvement in Pain/Discomfort2.514 (1.591--3.972)1.890 (1.159--3.083)2.937 (1.738--4.964)2.916 (1.643--5.177)2.789 (1.380--5.638)*CI* confidence interval

Discussion {#Sec7}
==========

The importance of assessing HRQoL in patients with advanced prostate cancer is increasingly recognized, and the PCWG2 recommends the use of validated questionnaires in clinical trials to characterize symptomatic outcome measures \[[@CR6]\]. Patient HRQoL was thus included as a prespecified endpoint in the PREVAIL study \[[@CR14]\]; these analyses provide important evidence on patients' own views of their health, complementing objective measures such as overall survival and radiographic progression. Indeed, improved HRQoL has been linked to better clinical outcomes in mCRPC \[[@CR21]\].

While many studies in mCRPC collect HRQoL data, to date this has been done using only disease-specific instruments. For example, it was previously shown that enzalutamide has HRQoL benefits relative to placebo in the post-chemotherapy setting using the FACT-P instrument \[[@CR22]\]. However, few trials have examined HRQoL outcomes in chemotherapy-naïve patients with mCRPC \[[@CR15], [@CR23]\]. Moreover, PREVAIL was the first trial to use EQ-5D to assess HRQoL in chemotherapy-naïve mCRPC \[[@CR15]\]. Although Loriot et al. \[[@CR15]\] showed that, compared with placebo, enzalutamide significantly prolonged the time to deterioration in EQ-5D index and VAS scores, the earlier paper did not present results for EQ-5D dimensions, and so was unable to ascertain what was driving the changes in summary scores. To expand on Loriot et al. \[[@CR15]\], we analyzed results primarily at the dimension and health-profile level and used different analytical approaches such as the PCHC, time-to-event analysis, and the number of patients reporting full health over time.

One advantage of this type of in-depth analysis is that the effects of treatment become clearer. For example, at first glance, Table [1](#Tab1){ref-type="table"} might be taken to indicate that patients remain relatively stable over the study period; e.g. no pain or discomfort was reported by 55.8% and 52.4% of patients in the enzalutamide group at baseline and at week 61, respectively. However, using the Paretian Classification of Change approach, when taking all dimensions together, there is considerable movement between levels of perceived problems, with outcomes favoring enzalutamide in terms of the proportion of patients improving and/or worsening, at all visits up to week 49. Simply presenting results as in Table [1](#Tab1){ref-type="table"}, while useful in providing an overall picture of change at the dimension level, fails to capture all of the effects on EQ-5D. Likewise, Table [3](#Tab3){ref-type="table"} shows that time to deterioration was consistently worse in the placebo group. This type of information can help provide a more complete picture of patient-reported outcome results. Indeed, time-to-event analyses indicate the protective effect of enzalutamide; for instance, the adjusted HR for \"moving away from baseline full health\" of 0.52 means that patients taking enzalutamide have about half the probability of worsening from baseline full health compared to those receiving placebo over the study period. In other words, for this outcome, the deterioration event rate in the enzalutamide arm is approximately half that of the placebo group.

The secondary analysis of data from PREVAIL reported here shows that, compared with placebo, enzalutamide was associated with significant HRQoL benefits in some but not all EQ-5D dimensions and that the delayed deterioration in overall HRQoL, as measured by the EQ-5D index and EQ-5D VAS, was largely driven by changes in the dimensions of Pain/Discomfort and Anxiety/Depression. There was no significant difference between enzalutamide and placebo groups in the Mobility and Self-care dimensions. Furthermore, PCHC analysis showed that the proportion of patients with improvements in HRQoL was significantly greater with enzalutamide than with placebo at the majority of time points.

Pain is one of the most prominent and debilitating symptoms for patients with mCRPC and skeletal metastases \[[@CR24]\]. In large clinical trials of patients with progressive CRPC, approximately 35% of patients had substantive pain \[[@CR6]\]. Pain is associated with a significant reduction in HRQoL \[[@CR1]\] and is a significant predictor of survival in mCRPC \[[@CR25], [@CR26]\]. However, pain is often under-treated in patients with cancer \[[@CR27], [@CR28]\], and in clinical trials in progressive prostate cancer early changes in pain are often not acted upon without other evidence of disease progression \[[@CR6]\]. The current analysis indicates that, based on data from the EQ-5D Pain/Discomfort domain, enzalutamide exhibited beneficial effects on pain and discomfort relative to placebo. Thus, the proportion of patients with no problems in this dimension was greater with enzalutamide than placebo from week 13 through to week 37, with a significant difference between groups during these time points. Additionally, time to first deterioration in the Pain/Discomfort dimension was significantly longer for enzalutamide. These results are consistent with the recommendation from the PCWG2 that effective treatments should delay and/or prevent HRQoL deterioration associated with disease progression, as well as delay the onset of significant pain in men with progressive CRPC \[[@CR6]\]. They also support previous analyses from the PREVAIL study showing that enzalutamide had beneficial effects on pain, as measured using the Brief Pain Inventory Short Form \[[@CR15]\].

We have also seen evidence of a beneficial effect of enzalutamide relative to placebo on anxiety and depression, with data from the EQ-5D Anxiety/Depression dimension favoring enzalutamide at week 13 and a significant delay in the time to first deterioration in Anxiety/Depression with enzalutamide. Depression and anxiety are two of the most common psychological symptoms in patients with cancer and are associated with poorer treatment outcomes, increased hospitalization, and higher mortality rates \[[@CR29]\]. In a recent meta-analysis of data from 27 articles in 4494 men with prostate cancer, the prevalence of clinical anxiety and depression was approximately 15% during treatment \[[@CR29]\]. However, evidence regarding psychological distress and effective psychological interventions for men with mCRPC is sparse; for example, the anxiety experienced varies greatly depending on individual circumstances \[[@CR3]\]. Also, a favorable prostate-specific antigen response can alleviate anxiety in men with prostate cancer.

Interestingly, the PREVAIL results suggest a moderate association between Pain/Discomfort and Anxiety/Depression, with the observation that a worsening or improvement in the Pain/Discomfort dimension was associated with a corresponding increase in the risk of worsening or improvement, respectively, in Anxiety/Depression in these patients with chemotherapy-naïve mCRPC. This is not unexpected as depressive and anxiety disorders have been shown to be associated with worse pain severity over time \[[@CR30]\], and pain has been shown to significantly correlate with depression in patients with advanced cancer \[[@CR31]\]. We would hypothesize that at least some of the Anxiety/Depression benefits observed are linked to effective control of disease.

In the large global patient population included in the current study, baseline EQ-5D index scores were slightly higher (indicating better health) than in other studies in patients with mCRPC \[[@CR2], [@CR32]--[@CR34]\], which might reflect the treatment (chemotherapy-naïve) and symptom (asymptomatic or mildly symptomatic) status of patients enrolled in PREVAIL. In fact, an interesting finding of this additional analysis is the high proportion of patients who report being in full health (i.e. EQ-5D health state 11111) at baseline. A recent analysis of EQ-5D-3L data from the 2012 Health Survey for England showed that, of the total sample of 7294 respondents from the general population, 56% reported full health \[[@CR35]\], compared with approximately 42% at baseline in the current study. However, in the present study, most patients (79%) were ≥65 years of age; for the male population in the 2012 Heath Survey for England, only 19% were aged \>65 years. Also of note was the high number of respondents in the enzalutamide group reporting full health at the final visit (*n* = 172/523 \[33%\] enzalutamide patients remaining in the study at week 61). Only 42 patients in the placebo group reported being in full health at week 61, although that represented 40.4% of the remaining patients (*n* = 117) receiving placebo, a number attributable to much higher rates of attrition.

The main limitation of our study was the high attrition rate, particularly in the placebo group, as a result of disease progression. This was expected, but it did limit the analyses due to the reduced sample size at later time points and the imbalance between groups in the numbers of patients. However, for time-to-event analysis, the attrition had less impact if the events happened, whereas the impact was actually greater on the time point analysis. It should also be noted that since attrition is nonrandom, after the majority of patients are off study drug, those left may comprise a subgroup of patients whose disease progresses slowly, even with placebo, or responds particularly well to the active treatment, thereby potentially biasing the results of analysis in favor of the placebo arm. Thus, analysis of those patients remaining on study suggested little or no difference between groups on any EQ-5D dimension toward the end of the study (week 61).

Another limitation of our analysis is the lack of HRQoL data after treatment discontinuation. However, patients are likely to be treated with other agents post-discontinuation, which could confound interpretation of the results. Finally, the nature of the patient population (high level of functioning; ECOG Performance Status of 0 or 1; asymptomatic/mildly symptomatic) may not reflect the real-world population of men with mCRPC, which limits the generalizability of the results. Further epidemiological research could show the extent to which the PREVAIL study population is representative of the mCRPC population seen in clinical practice.

Conclusions {#Sec8}
===========

In conclusion, in this population of patients with chemotherapy-naïve mCRPC from the PREVAIL trial, this post hoc analysis of EQ-5D data at the dimension level showed that enzalutamide was associated with significant benefits in terms of Pain/Discomfort and Anxiety/Depression compared with placebo and may help to support future analyses of this type. There was some evidence that benefits in the Anxiety/Depression dimension were associated with patient evolution in the Pain/Discomfort dimension, but further investigation is required. Also of note was the relatively high proportion of patients reporting full health on EQ-5D both at baseline and end of study, with proportions that are likely similar to those reporting full health in general population samples; this suggests that enzalutamide can help substantial numbers of patients with mCRPC to maintain a quality of life approaching that of similarly aged samples of the general population.

AR

:   Androgen receptor

CI

:   Confidence interval

CRPC

:   Castration-resistent prostate cancer

ECOG

:   Eastern Cooperative Oncology Group

EQ-5D VAS

:   EQ-5D visual analogue scale

FACT-P

:   Functional assessment of cancer therapy--prostate

HR

:   Hazard ratio

HRQoL

:   Health-related quality of life

LSM

:   Least squares mean

mCRPC

:   Metastatic castration-resistent prostate cancer

PCHC

:   Paretian classification of health change

PCWG2

:   Prostate Cancer Clinical Trials Working Group 2.

Medical writing assistance was provided by Thomas Lavelle of Bioscript Science and editorial assistance was provided by Shannon Davis of Ashfield Healthcare Communications (Middletown, CT, USA), both funded by the study sponsors.

Funding {#FPar1}
=======

This study was funded by Astellas Pharma, Inc., and Medivation, Inc. (Medivation was acquired by Pfizer, Inc., in September 2016), the co-developers of enzalutamide.

Availability of data and materials {#FPar2}
==================================

Data used in these analysis are not publically available as this could jeopardize reimbursement in some markets where confidential commercial agreements exist. If readers wish to request data, they may do so in writing. Interested parties should contact Shevani Naidoo at Shevani.Naidoo\@astellas.com.

Authors' contributions {#FPar3}
======================

ND, MH, MP, DP, SN, CI, and SH contributed to the conception and design of the analysis, and to data analysis and interpretation. All authors contributed to the writing and critical review of the manuscript, and all authors read and approved the final manuscript.

Competing interests {#FPar4}
===================

DP, SH, and SN are employees of Astellas. TP and MB are employees of Medivation. ND and MH are employees of the Office of Health Economics (OHE), which received consulting fees from Astellas for the analysis and interpretation of EQ-5D data from the PREVAIL trial and has received consulting fees and research grants for other Astellas projects. MP was contracted by OHE to perform the analysis of EQ-5D data from the PREVAIL trial. TMB received grants for research funding from Astellas Pharma Global, Janssen Research & Development, and Medivation, personal (consultancy) fees from Astellas Pharma Global and Janssen Japan, and payment from Research to Practice for participation in a Certified Nursing Education program, which was supported in part by Medivation and Astellas Pharma Global. BT received grants, personal fees and non-financial support from Astellas and personal fees from Medivation. YL received personal fees from Astellas (advisory board, speaker, honoraria and travel) and from Medivation (advisory board and speaker). CI is an employee of Quintiles, which received funding from Astellas to conduct the analyses reported here.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

PREVAIL was approved by the independent review board at each participating site and was conducted according to the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Conference on Harmonisation. All patients provided written informed consent before participating in the trial.
